# Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

> **NCT03471117** · PHASE4 · RECRUITING · sponsor: **The University of Texas at Arlington** · enrollment: 28 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Pioglitazone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03471117
- **Lead sponsor:** The University of Texas at Arlington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03471117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03471117, "Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03471117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*